Sida i infecció per VIH
Línies de recerca
-
Therapeutic aspects
The following lines are mainly focussed on clinical and diagnostic features of HIV & co-infection:
- HCV and HBV coinfection. Efficacy and safety of new direct-antiviral drugs (DAA) against HCV. Long- term follow up of patients treated with DAA. Strategies toward HCV eradication
- Antiretroviral treatment: efficacy and safety of new antiretroviral drugs
- Studies of resistance
- New antiretroviral strategies
- Primary HIV infection: eradication and functional cure strategies
- Use of Tirosine Knase inhibitors as a new strategy for HIV cure
-
Clinical and diagnostic aspects
- Pharmacogenomics and pharmacokinetics
- Opportunistic diseases associated to HIV infection: tuberculosis, human papillomavirus, anal cancer
- Solid organ transplantation in HIV-infected patients
- Incidence and management of non-AIDS defining events including infections, cardiovascular diseases, frailty, cancer and accelerated aging.
- Early diagnosis and treatment of HCV reinfection
- Pregnancy and HIV
- Impact evolution and prognostic factor of COVID-19 in HIV patients
- Immunological response of HIV patients to SARS-CoV-2 vaccines
-
Basic and translational research
- Immuno-pathogenesis of HIV infection and mechanisms of HIV control
- Generation of new immunogens based on defective HIV-based vectors
- Development of new therapeutic vaccines platforms: dendritic cells and RNA-based vaccines
- Preventive vaccines based on the envelope of Transmitted-Founder Viruses
- Studies on the HIV reservoirs in different clinical situations. Impact of tumour events in the maintenance of viral reservoirs.
- Impact of tumour events in the maintenance of viral reservoirs
- Studies on the modulation of microbiota in HIV-infected patients
- Studies on senescence in HIV patients: molecular mechanisms and clinical implication
-
Epidemiological research and public health
- Epidemiological studies based on cohorts (PISCIS, ART-CC, COHERE, EuroSida. PROBE-C)
- STDs in HIV-infected patients. Epidemiology, diagnosis, treatment, and prevention
- Prevention strategies: PEP and PrEP
- Sexualised drug use. Early diagnosis and treatment of HIV, HCV and other STI in this high risk population. 'Chemsex' multidisciplinary management
- New health-care strategies: telemedicine, shared health-care unit with primary care and OPAT programs
- HIV infection in adolescent population
- Anal cancer prevention program in immunosuppressed individuals
- Chemsex management in MSM population